相关实验视频

Updated: Jul 11, 2025

Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum

Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum

Published on: May 3, 2024

雄黄丸通过POU4F1/STAT3轴促进质瘤细胞烧灭

Ning Tang¹, Yuanyuan Zhu¹, Jianbai Yu²

¹Department of Neurosurgery, The First Affiliated Hospital of Hunan University of Chinese Medicine, No. 95 Shaoshan Middle Road, Changsha, Hunan, 410007, People's Republic of China.

Functional & integrative genomics

|November 14, 2023

概括

雄黄药 (XHP) 通过向POU4F1/STAT3途径诱导质瘤细胞灭,抑制瘤生长. 这种传统中医药在治疗中枢神经系统恶性瘤方面显示出潜力.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
传统中国医药传统中国医药

背景情况:

质瘤是最常见的中枢神经系统恶性瘤.
了解驱动质瘤进展的分子机制对于开发有效疗法至关重要.

研究的目的:

为了研究黄药 (XHP) 对质瘤细胞火的作用.
阐明XHP对质瘤作用的分子机制.

主要方法:

瘤细胞 (U251,SHG-44) 用XHP,POU4F1过度表达或STAT3沉默进行治疗.
检测包括CCK8,流细胞计,显微镜,LDH检测,ELISA,免疫光和西部斑点.
一个初级质瘤模型被用于体内验证.

主要成果:

治疗XHP降低了质瘤细胞的活力,并促进了灭,由形态变化和增加的LDH,IL-1β和IL-18水平证明.
在XHP调节的与热相关的蛋白质 (NLRP3,ASC,分裂的caspase-1) 和下调的POU4F1和STAT3.
POU4F1作为STAT3的转录因子,其过度表达或STAT3沉默抑制了XHP诱导的热.
在体内研究证实了XHP增强热和抑制质瘤生长的能力.

结论:

雄黄丸通过POU4F1/STAT3信号轴促进质瘤细胞灭.
通过诱导编程细胞死亡和阻断瘤进展,XHP证明了对质瘤的治疗潜力.

关键词:

质瘤是一种质瘤.在 POU4F1F1 中.热性灭症 (Pyroptosis) 是一种在STAT3中,我们可以使用STAT3.转录翻译翻译西黄的药丸是一种药丸.

更多相关视频

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model

Published on: June 4, 2017

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...